WuXi AppTec Co., Ltd. (BKK:WUXIAT80)

Thailand · Delayed Price · Currency is THB

5.40

+0.05 (0.93%)

At close: May 25, 2026

Market Cap	1.49T +101.6%
Revenue (ttm)	218.61B +23.4%
Net Income	95.25B +80.1%
EPS	32.66 +77.9%
Shares Out	n/a
PE Ratio	15.61
Forward PE	16.69
Dividend	0.07 (1.36%)
Ex-Dividend Date	May 13, 2026

Volume	27,790
Open	5.45
Previous Close	5.35
Day's Range	5.40 - 5.45
52-Week Range	3.96 - 6.05
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 27, 2026

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula... [Read more]

Industry Commercial Physical and Biological Research

Founded 2000

Employees 33,834

Stock Exchange Stock Exchange of Thailand

Ticker Symbol WUXIAT80

Financial Performance

In 2025, WuXi AppTec's revenue was 43.42 billion, an increase of 21.40% compared to the previous year's 35.77 billion. Earnings were 19.15 billion, an increase of 102.65%.

Financial numbers in CNY Financial Statements

News

WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index

SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Bes...

8 days ago - PRNewsWire

WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026

Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion Backlog for Continuing Operations Up 23.6% YoY to...

4 weeks ago - PRNewsWire

WuXi AppTec Slides: Q1 2026

WuXi AppTec has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 27, 2026.

4 weeks ago - Filings

WuXi AppTec Quarterly report: Q1 2026

WuXi AppTec has published its Q1 2026 quarterly earnings report on April 27, 2026.

4 weeks ago - Filings

WuXi AppTec Earnings Call Transcript: H2 2025

Record 2025 results with revenue up 21.4% and adjusted net profit up 41.3% year-over-year. 2026 guidance targets 18–22% revenue growth, robust cash flow, and continued global expansion, supported by a strong backlog and resilient business model.

2 months ago - Transcripts

WuXi AppTec Annual report: H2 2025

WuXi AppTec has published its H2 2025 annual report on March 23, 2026.

2 months ago - Filings

WuXi AppTec Slides: H2 2025

WuXi AppTec has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 23, 2026.

2 months ago - Filings

WuXi AppTec Beat Full-Year Guidance and Achieved Record Performance in 2025

2025 Total Revenue Reached RMB 45.46 Billion; Revenue from Continuing Operations Up 21.4% YoY Adjusted Non-IFRS Net Profit Up 41.3% YoY to RMB 14.96 Billion Backlog for Continuing Operations Up 28.8% ...

2 months ago - PRNewsWire

WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership

SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized...

4 months ago - PRNewsWire

WuXi AppTec Transcript: 44th Annual J.P. Morgan Healthcare Conference

Record 2025 revenue and profit were driven by strong demand in GLP-1, peptides, and small molecules, with significant capacity expansions and robust global customer growth. The company maintained high ESG standards, returned substantial value to shareholders, and expects continued growth in 2026.

4 months ago - Transcripts

WuXi AppTec Slides: 44th Annual J.P. Morgan Healthcare Conference

WuXi AppTec has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.

4 months ago - Filings

WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry

SHANGHAI, MIDDLETOWN, Del. and MUNICH , Nov. 19, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been reco...

6 months ago - PRNewsWire

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health

SHANGHAI , Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategi...

7 months ago - PRNewsWire

WuXi AppTec Earnings Call Transcript: Q3 2025

Record revenue and profit growth in the first three quarters, driven by strong performance in small molecule and TIDES businesses, with robust backlog and improved margins. Raised full-year guidance, accelerated global expansion, and announced divestiture of China-based clinical research services.

7 months ago - Transcripts

WuXi AppTec Quarterly report: Q3 2025

WuXi AppTec has published its Q3 2025 quarterly earnings report on October 26, 2025.

7 months ago - Filings

WuXi AppTec Slides: Q3 2025

WuXi AppTec has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 26, 2025.

7 months ago - Filings

WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance

SHANGHAI, Oct. 26, 2025 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pha...